Dr. Rockx received his PhD from Utrecht University in 2004 for studies on Norovirus susceptibility and antibody responses. Following
his PhD, Barry moved to the USA where he initially worked on the evolution and pathogenesis of SARS-CoV and the development of broadly reactive therapeutic antibodies as a post-doctoral fellow at the University of North Carolina. He subsequently joined
the Laboratory of Virology at the Rocky Mountain Laboratories of the National Institutes of Health in Montana where he studied the pathogenesis and vaccine development of SARS-CoV, influenza, henipaviruses and filoviruses. He continued this line of
research as a tenure-track Assistant Professor at the University of Texas Medical Branch. In 2014, Barry returned to The Netherlands as Head of the Department of Rare and Emerging Viral Infections and Response at the Center for Infectious Disease
Control of the National Institute for Public Health and the Environment in Bilthoven. Since 2016, Barry is Head of the Exotic Viruses Workgroup in the Department of Viroscience at Erasmus MC.
His main research involves studies on the tropism, pathogenesis and host responses of emerging zoonotic viruses causing hemorrhagic, respiratory and neurological diseases, including orthohantaviruses and arboviruses in a variety of in vitro and in vivo models at. He has authored over 50 peer-reviewed scientific publications, several book chapters and has supervised several post-doctoral fellows and students. He has coordinated several NIH funded projects and contracts, and is
currently Taskleader in EU Horizon 2020 and ZonMw funded projects.
Search PubMed for Dr. Rockx' publications.